Kyowa Kirin to Present Important Findings on Rocatinlimab at EADV 2025 Congress
On July 29, 2025, Kyowa Kirin Co., Ltd. announced that crucial findings from their Phase 3 study of Rocatinlimab will be showcased at the European Academy of Dermatology and Venereology (EADV) 2025 Annual Meeting. This event will take place in Paris, France, from September 17 to 20, 2025. Rocatinlimab is an investigational therapy designed to target the OX40 receptor, with a focus on patients suffering from moderate to severe atopic dermatitis (AD).
Atopic dermatitis is a chronic inflammatory condition characterized by dry, itchy skin that can severely impact the quality of life for affected individuals. The disease is often exacerbated by flare-ups, leading to relentless scratching and increased susceptibility to skin infections. Approximately 15-20% of children and up to 10% of adults are diagnosed with AD. It arises from a disruption in skin barrier functions and an imbalance of T cells, which contribute to inflammatory responses. These T cells manifest particularly through the expansion of OX40R+ pathogenic T cells, which play a key role in the onset and persistence of AD symptoms.
The abstract presentation during the congress will detail the efficacy and safety data of Rocatinlimab, emphasizing its potential as a first-in-class T-cell rebalancing therapy that not only inhibits pathogenic T cells but also fosters a healthier immune response by targeting the OX40 receptor.
The presentation is scheduled for September 19, 2025, from 4:40 to 4:50 PM CEST, in the session dedicated to Atopic Dermatitis at the Paris Convention Centre. Emma Guttman-Yassky, MD, PhD, will lead the presentation, which promises to be a significant contribution to the field, given the challenges faced by those living with moderate to severe atopic dermatitis.
The ROCKET Phase 3 Program is expansive, consisting of eight studies that together aim to validate the safety and efficacy profile of Rocatinlimab across various dosing regimens. Early results have indicated optimism in its ability to mitigate the severe itching, inflammation, and skin damage associated with atopic dermatitis.
As a clinical candidate, Rocatinlimab is not just limited to atopic dermatitis; it is also being explored for other conditions linked to T-cell imbalance, including prurigo nodularis and uncontrolled asthma. The initial antibody for Rocatinlimab was discovered through collaborative efforts between Kyowa Kirin and the La Jolla Institute for Immunology.
Kyowa Kirin's broader mission is centered on discovering and delivering innovative medicines that significantly enhance patient quality of life. The company has been instrumental in developing biotechnology advancements for over 70 years, aiming to address unmet medical needs. Following a strategic collaboration with Amgen in June 2021, the commercialization and development efforts for Rocatinlimab are positioned for global reach while retaining specific rights for local markets, notably in Japan.
In conclusion, the upcoming presentation at the EADV Congress represents a pivotal moment for Kyowa Kirin, not only spotlighting their innovative approach to treating atopic dermatitis but also reaffirming their commitment to addressing significant challenges in dermatological healthcare. The findings welcome a new horizon for patients grappling with the debilitating effects of atopic dermatitis and signal hope for future therapeutic options that prioritized patient well-being and improved quality of life.
Atopic dermatitis is a chronic inflammatory condition characterized by dry, itchy skin that can severely impact the quality of life for affected individuals. The disease is often exacerbated by flare-ups, leading to relentless scratching and increased susceptibility to skin infections. Approximately 15-20% of children and up to 10% of adults are diagnosed with AD. It arises from a disruption in skin barrier functions and an imbalance of T cells, which contribute to inflammatory responses. These T cells manifest particularly through the expansion of OX40R+ pathogenic T cells, which play a key role in the onset and persistence of AD symptoms.
The abstract presentation during the congress will detail the efficacy and safety data of Rocatinlimab, emphasizing its potential as a first-in-class T-cell rebalancing therapy that not only inhibits pathogenic T cells but also fosters a healthier immune response by targeting the OX40 receptor.
The presentation is scheduled for September 19, 2025, from 4:40 to 4:50 PM CEST, in the session dedicated to Atopic Dermatitis at the Paris Convention Centre. Emma Guttman-Yassky, MD, PhD, will lead the presentation, which promises to be a significant contribution to the field, given the challenges faced by those living with moderate to severe atopic dermatitis.
The ROCKET Phase 3 Program is expansive, consisting of eight studies that together aim to validate the safety and efficacy profile of Rocatinlimab across various dosing regimens. Early results have indicated optimism in its ability to mitigate the severe itching, inflammation, and skin damage associated with atopic dermatitis.
As a clinical candidate, Rocatinlimab is not just limited to atopic dermatitis; it is also being explored for other conditions linked to T-cell imbalance, including prurigo nodularis and uncontrolled asthma. The initial antibody for Rocatinlimab was discovered through collaborative efforts between Kyowa Kirin and the La Jolla Institute for Immunology.
Kyowa Kirin's broader mission is centered on discovering and delivering innovative medicines that significantly enhance patient quality of life. The company has been instrumental in developing biotechnology advancements for over 70 years, aiming to address unmet medical needs. Following a strategic collaboration with Amgen in June 2021, the commercialization and development efforts for Rocatinlimab are positioned for global reach while retaining specific rights for local markets, notably in Japan.
In conclusion, the upcoming presentation at the EADV Congress represents a pivotal moment for Kyowa Kirin, not only spotlighting their innovative approach to treating atopic dermatitis but also reaffirming their commitment to addressing significant challenges in dermatological healthcare. The findings welcome a new horizon for patients grappling with the debilitating effects of atopic dermatitis and signal hope for future therapeutic options that prioritized patient well-being and improved quality of life.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.